BioLineRx (BLRX) Cash & Equivalents (2010 - 2026)

BioLineRx's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $3.2 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 68.86% year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $3.2 million (down 68.86% YoY), while the FY2025 annual figure was $3.2 million, down 68.86% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $3.2 million, down from $7.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $17.5 million in Q2 2021, with the low at $3.2 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $9.9 million (2023), against an average of $10.2 million.
• The sharpest annual moves came in 2021 and 2025: Cash & Equivalents surged 216.57% in 2021, then tumbled 68.86% in 2025.
• BioLineRx's Cash & Equivalents stood at $13.0 million in 2021, then slipped by 18.5% to $10.6 million in 2022, then sank by 59.81% to $4.3 million in 2023, then surged by 145.26% to $10.4 million in 2024, then sank by 68.86% to $3.2 million in 2025.
• Business Quant data shows BLRX's Cash & Equivalents at $3.2 million in Q4 2025, $7.9 million in Q3 2025, and $7.2 million in Q2 2025.